Abstract
Background Up-to-date evidence on levels and trends for age-sex-specific all-cause and cause-specific mortality is essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess whether there is epidemiological convergence across countries. Methods We estimated age-sex-specific all-cause mortality using the GBD 2010 methods with some refinements to improve accuracy applied to an updated database of vital registration, survey, and census data. We generally estimated cause of death as in the GBD 2010. Key improvements included the addition of more recent vital registration data for 72 countries, an updated verbal autopsy literature review, two new and detailed data systems for China, and more detail for Mexico, UK, Turkey, and Russia. We improved statistical models for garbage code redistribution. We used six different modelling strategies across the 240 causes; cause of death ensemble modelling (CODEm) was the dominant strategy for causes with sufficient information. Trends for Alzheimer's disease and other dementias were informed by meta-regression of prevalence studies. For pathogen-specific causes of diarrhoea and lower respiratory infections we used a counterfactual approach. We computed two measures of convergence (inequality) across countries: the average relative difference across all pairs of countries (Gini coefficient) and the average absolute difference across countries. To summarise broad findings, we used multiple decrement life-tables to decompose probabilities of death from birth to exact age 15 years, from exact age 15 years to exact age 50 years, and from exact age 50 years to exact age 75 years, and life expectancy at birth into major causes. For all quantities reported, we computed 95% uncertainty intervals (UIs). We constrained cause-specific fractions within each age-sex-country-year group to sum to all-cause mortality based on draws from the uncertainty distributions. Findings Global life expectancy for both sexes increased from 65·3 years (UI 65·0-65·6) in 1990, to 71·5 years (UI 71·0-71·9) in 2013, while the number of deaths increased from 47·5 million (UI 46·8-48·2) to 54·9 million (UI 53·6-56·3) over the same interval. Global progress masked variation by age and sex: for children, average absolute differences between countries decreased but relative differences increased. For women aged 25-39 years and older than 75 years and for men aged 20-49 years and 65 years and older, both absolute and relative differences increased. Decomposition of global and regional life expectancy showed the prominent role of reductions in age-standardised death rates for cardiovascular diseases and cancers in high-income regions, and reductions in child deaths from diarrhoea, lower respiratory infections, and neonatal causes in low-income regions. HIV/AIDS reduced life expectancy in southern sub-Saharan Africa. For most communicable causes of death both numbers of deaths and age-standardised death rates fell whereas for most non-communicable causes, demographic shifts have increased numbers of deaths but decreased age-standardised death rates. Global deaths from injury increased by 10·7%, from 4·3 million deaths in 1990 to 4·8 million in 2013; but age-standardised rates declined over the same period by 21%. For some causes of more than 100 000 deaths per year in 2013, age-standardised death rates increased between 1990 and 2013, including HIV/AIDS, pancreatic cancer, atrial fibrillation and flutter, drug use disorders, diabetes, chronic kidney disease, and sickle-cell anaemias. Diarrhoeal diseases, lower respiratory infections, neonatal causes, and malaria are still in the top five causes of death in children younger than 5 years. The most important pathogens are rotavirus for diarrhoea and pneumococcus for lower respiratory infections. Country-specific probabilities of death over three phases of life were substantially varied between and within regions. Interpretation For most countries, the general pattern of reductions in age-sex specific mortality has been associated with a progressive shift towards a larger share of the remaining deaths caused by non-communicable disease and injuries. Assessing epidemiological convergence across countries depends on whether an absolute or relative measure of inequality is used. Nevertheless, age-standardised death rates for seven substantial causes are increasing, suggesting the potential for reversals in some countries. Important gaps exist in the empirical data for cause of death estimates for some countries; for example, no national data for India are available for the past decade. Funding Bill & Melinda Gates Foundation.
Original language | English |
---|---|
Pages (from-to) | 117-171 |
Number of pages | 55 |
Journal | Lancet |
Volume | 385 |
Issue number | 9963 |
DOIs | |
Publication status | Published - 10 Jan 2015 |
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Lancet, Vol. 385, No. 9963, 10.01.2015, p. 117-171.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
AU - Murray, Christopher
AU - wang, Haidong
AU - Lozano, Rafael
AU - Davis, Adrian
AU - Liang, Xiaofeng
AU - Zhou, Maigeng
AU - Vollset, Stein
AU - Ozgoren, Ayse Abbasoglu
AU - Abdalla, Safa
AU - Abd-Allah, Foad
AU - Aziz, Muna
AU - Abera, Semaw Ferede
AU - Aboyans, Victor
AU - Abraham, Biju
AU - Abuabara, Katrina
AU - Abubakar, Ibrahim
AU - Abu-Raddad, Laith
AU - Abu-Rmeileh, Niveen
AU - Achoki, Tom
AU - Adelekan, Ademola
AU - Ademi, Zanfina
AU - Adofo, Koranteng
AU - Adou, Arsene
AU - Adsuar, Jose
AU - Arnlov, Johan
AU - Al Khabouri, Mazin
AU - Alasfoor, Deena
AU - Albittar, Mohammed
AU - Alegretti, Miguel
AU - Aleman, Alicia
AU - Alemu, Zewdie Aderaw
AU - Alfonso-Cristancho, Rafael
AU - Alhabib, Samia
AU - Ali, Mohammed
AU - Ali, Raghib
AU - Alla, Francois
AU - Al Lami, Faris
AU - Allebeck, Peter
AU - AlMazroa, Mohammad
AU - Al-Shahi Salman, Rustam
AU - Alsharif, Ubai
AU - Alvarez, Elena
AU - Alviz-Guzman, Nelson
AU - Amankwaa, Adansi
AU - Badawi, Alaa
AU - Bahit, Maria
AU - Bakfalouni, Talal
AU - Balakrishnan, Kalpana
AU - Balalla, Shivanthi
AU - Banerjee, Amitava
AU - Barber, Ryan
AU - Barker-Collo, Suzanne
AU - Barquera, Simon
AU - Barregard, Lars
AU - Barrero, Lope
AU - Barrientos-Gutierrez, Tonatiuh
AU - Basu, Arindam
AU - Basulaiman, Mohammed
AU - Beardsley, Justin
AU - Charlson, Fiona
AU - Che, Xuan
AU - Chen, Honglei
AU - Chen, Yingyao
AU - Chen, Jian Sheng
AU - Chen, Zhengming
AU - Chiang, Peggy
AU - Chimed-Ochir, Odgerel
AU - Chowdhury, Rajiv
AU - Christensen, Hanne
AU - Christophi, Costas
AU - Deribe, Kebede
AU - Jarlais, Don
AU - Dessalegn, Muluken
AU - DeVeber, Gabrielle
AU - Dharmaratne, Samath
AU - Diaz-Ortega, Jose-Luis
AU - Diaz-Torne, Cesar
AU - Dicker, Daniel
AU - Ding, Eric
AU - Dokova, Klara
AU - Dorsey, E
AU - Driscoll, Tim
AU - Duan, Leilei
AU - Edmond, Karen
AU - Ellenbogen, Richard
AU - Elshrek, Yousef
AU - Furst, Thomas
AU - Fahimi, Saman
AU - Fahrion, Anna
AU - Faraon, Emerito
AU - Fay, Derek
AU - Feigl, Andrea
AU - Feigin, Valery
AU - Ginawi, Ibrahim
AU - Giroud, Maurice
AU - Glaser, Elizabeth
AU - Goenka, Shifalika
AU - Dantes, Hector
AU - Gona, Philimon
AU - Gonzalez-Medina, Diego
AU - Guinovart, Caterina
AU - Gupta, Rahul
AU - Gosselin, Richard
AU - Gotay, Carolyn
AU - Goto, Atsushi
AU - Haagsma, Juanita
AU - Hafezi-Nejad, Nima
AU - Hagan, Holly
AU - Hagstromer, Maria
AU - Halasa, Yara
AU - Hamadeh, Randah
AU - Hamavid, Hannah
AU - Hammami, Mouhanad
AU - Hancock, Jamie
AU - Hankey, Graeme
AU - Hansen, Gillian
AU - Ohkubo, Takayoshi
AU - Iannarone, Marissa
AU - Iburg, Kim
AU - Idrisov, Bulat
AU - Ikeda, Nayu
AU - Innos, Kaire
AU - Inoue, Manami
AU - Islami, Farhad
AU - Jacobsen, Kathryn
AU - Jassal, Simerjot
AU - Jayaraman, Sudha
AU - Jensen, Paul
AU - Jha, Vivekanand
AU - Jiang, Guohong
AU - Jiang, Ying
AU - Jonas, Jost
AU - Joseph, Jonathan
AU - Juel, Knud
AU - Kabagambe, Edmond
AU - Kan, Haidong
AU - Karch, Andre
AU - Karimkhani, Chante
AU - Karthikeyan, Ganesan
AU - Kassebaum, Nicholas
AU - Kaul, Anil
AU - kawakami, Norito
AU - Kazanjan, Konstantin
AU - Kazi, Dhruv
AU - Kemp, Andrew
AU - Kengne, Andre
AU - Keren, Andre
AU - Kereselidze, Maia
AU - Khader, Yousef
AU - Kinfu, Yohannes
AU - Lalloo, Ratilal
AU - Lallukka, Tea
AU - Lam, Hilton
AU - Lan, Qing
AU - Lansingh, Van
AU - Larson, Heidi
AU - Larsson, Anders
AU - Lavados, Pablo
AU - Lawrynowicz, Alicia
AU - Leasher, Janet
AU - Lee, Jong-Tae
AU - Leigh, James
AU - Leinsalu, Mall
AU - Leung, Ricky
AU - Levitz, Carly
AU - Mahdi, Abbas
AU - Majdan, Marek
AU - Malekzadeh, Reza
AU - Mangalam, Srikanth
AU - Mapoma, Christopher
AU - Marape, Marape
AU - MArcenes, wagner
AU - Margono, Christopher
AU - Marks, Guy
AU - Marzan, Melvin
AU - Masci, Joseph
AU - Mashal, Mohammad
AU - Nangia, Vinay
AU - Narayan, K
AU - Nash, Denis
AU - Nejjari, Chakib
AU - Nasher, Jamal
AU - Nelson, Robert
AU - Neuhouser, Marian
AU - Neupane, Sudan
AU - Newcomb, Polly
AU - Newton, Charles
AU - Ng, Marie
AU - Ngalesoni, Frida
AU - Nguyen, Grant
AU - Nguyen, Nhung
AU - Nisar, Muhammad
AU - Odell, Shaun
AU - O'Donnell, Martin
AU - Ohno, Summer
AU - Olusanya, Bolajoko
AU - Omer, Saad
AU - Opio, John
AU - Orisakwe, Orish
AU - Ortblad, Katrina
AU - Ortiz, Alberto
AU - Otayza, Maria
AU - Pavlin, Boris
AU - Pearce, Niel
AU - Pellegrini, Carlos
AU - Pereira, David
AU - Peresson, Sophie
AU - Perez-Padilla, Rogelio
AU - Perez-Ruiz, Fernando
AU - Perico, Norberto
AU - Pervaiz, Aslam
AU - Pesudovs, Konrad
AU - Peterson, Carrie
AU - Petzold, Max
AU - Phillips, Bryan
AU - Qato, Dima
AU - Quezada, Amado
AU - Quistberg, D
AU - Raju, Murugesan
AU - Rakovac, Ivo
AU - Rana, Saleem
AU - Refaat, Amany
AU - Remuzzi, Giuseppe
AU - Ribeiro, Antonio
AU - Ricci, Stefano
AU - Riccio, Patricia
AU - Richardson, Lee
AU - Richardus, Jan
AU - Roberts, Bayard
AU - Saha, Sukanta
AU - Sahathevan, Ramesh
AU - Sahraian, Mohammad
AU - Sahle, Berhe
AU - Salomon, Joshua
AU - Salvo, Deborah
AU - Samonte, Genesis
AU - Sampson, Uchechukwu
AU - Sanabria, Juan
AU - Sandar, Logan
AU - Santos, Itamar
AU - Tenkorang, Eric
AU - Terkawi, Abdullah
AU - Thomas, Bernadette
AU - Thorne-Lyman, Andrew
AU - Thrift, Amanda
AU - Thurston, GEorge
AU - Tillmann, Taavi
AU - Tirschwell, David
AU - Tleyjeh, Imad
AU - Tonelli, Marcello
AU - Topouzis, Fotis
AU - Towbin, Jeffrey
AU - Ubeda, Clotilde
AU - Uchendu, Uche
AU - Undurraga, Eduardo
AU - Vallely, Andrew
AU - Van De Vijver, Steven
AU - Van Gool, Coen
AU - Varakin, Yuri
AU - Vasankari, Tommi
AU - Vasconcelos, Ana
AU - Wagner, Gregory
AU - Waller, Stephen
AU - Wang, Jianli
AU - Wang, Linhong
AU - Wang, XiaoRong
AU - Warouw, Tati
AU - Weichenthal, Scott
AU - Weiderpass, Elisabete
AU - Weintraub, Robert
AU - Wenzhi, Wang
AU - Xu, Gelin
AU - Yang, Rebecca
AU - Yano, Yuichiro
AU - Yatsuya, Hiroshi
AU - Yip, Paul
AU - Yonemoto, Naohiro
AU - Yoon, Seok-Jun
AU - Younis, Mustafa
AU - Yu, Chuanhua
AU - Zhu, Jun
AU - Zhu, Shankuan
AU - Zonies, Davies
AU - Zou, Xiao
AU - Zunt, Joseph
AU - Vos, Theo
AU - lopez, Alan
AU - Gosslin, R
AU - Karam, Nadim
AU - Sabin, Nsanzimana
AU - Temesgen, A
N1 - Funding Information: BDG works for AMP, which receives grant support for vaccine and immunisation related work from Crucell, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi Pasteur; however, none of this support is for work related to the present report. KJ reports has consulted for GlaxoSmithKline on projects outside the submitted work. WM is program analyst at the UNFPA country office in Peru, which does not necessarily endorse the study. JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, and Allergan. JAS is a member of the executive of OMERACT, which receives funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. RFG is associate editor of Annals of Epidemiology for which he receives a stipend. CK receives research grants from Brazilian public funding agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS). He has also received authorship royalties from publishers Artmed and Manole. GR has consultancy agreements with Alexion Pharmaceuticals, Reata Pharmaceuticals, Bayer Healthcare, and Novartis Pharma, and is a member of the Abbvie Atrasentan Steering Committee; GR does not accept personal remuneration, compensations are paid to his institution for research and educational activities. MDH has received research support from the National Heart, Lung, and Blood Institute and World Heart Federation for its Emerging Leaders program, which is supported by unrestricted educational grants from AstraZeneca and Boehringer Ingelheim. FP-R has received investigation grants from Ministerio de Sanidad, Gobierno de España, Asociación de Reumatólogos del Hospital de Cruces, Fundación Española de Reumatología; has been a consultant (with or without payment) for Astra-Zeneca, Menarini, Metabolex, Ardea Biosciences, SOBI, Novartis, and Pfizer; and has been a speaker for AstraZeneca and Menarini. KBG received the NHMRC-Gustav Nossai scholarship sponsored by CSL Behring in 2013. MGS has previously served as consultant for Ethicon on global surgery. PJ is supported by a career development fellowship from the Wellcome Trust, Public Health Foundation of India, and a consortium of UK universities. DAQ was supported by The Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (number 5T32HD057822). AK has received institutional support (intramural funding) from the Oklahoma State University Center for Health Sciences. RAL receives funding through the Farr Institute of Health Informatics Research. The Farr Institute is supported by Arthritis Research UK, British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Engineering and Physical Sciences Research Council, Medical Research Council, National Institute of Health Research, National Institute for Social Care and Health Research (Welsh Government), and the Chief Scientist Office (Scottish Government Health Directorates), (MRC grant MR/K006525/1). DM reports ad hoc honoraria from Bunge, Pollock Institute, and Quaker Oats; ad hoc consulting for Foodminds, Nutrition Impact, Amarin, AstraZeneca, Winston and Strawn LLP, and Life Sciences Research Organization; membership of Unilever North America Scientific Advisory Board; and chapter royalties from UpToDate. RD and LB are employed by the US Department of Veterans Affairs. VC is on the speaker bureau for Boehringer Ingelheim Baker. MS is an employee of Novartis Pharma. All other authors declare no competing interests. The authors alone are responsible for the views expressed in this Article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. Funding Information: We thank the countless individuals who have contributed to the Global Burden of Disease Study 2013 in various capacities. We acknowledge the extensive support from all staff members at the Institute for Health Metrics and Evaluation and specifically thank: Kelsey Pierce for her valuable guidance; James Bullard, Serkan Yalcin, Evan Laurie, and Andrew Ernst for their tireless support of the computational infrastructure required to produce the results; Linda A Ettinger for her expert administrative support; and Peter Speyer and Eden Stork for their persistent and invaluable work to gain access to and catalogue as much data as possible to inform the estimates. We also acknowledge the support of the Rwandan Ministry of Health's GBD Team, led by Agnes Binagwaho, for their collaboration and for reviewing the manuscript: Uwaliraye Parfait, Karema Corine, Jean Pierre Nyemazi, Sabin Nsanzimana, Yvonne Kayiteshonga, Marie Aimee Muhimpundu, Jean de Dieu Ngirabega, Ida Kankindi, Sayinzoga Felix, and Gasana Evariste. The following individuals acknowledge various forms of institutional support. RA-SS was funded by a UK MRC senior clinical fellowship. SB acknowledges additional funding or institutional support from International Development Research Center of Canada, Stanford University, and Rosenkranz Price for health-care research in developing countries. AR was supported by research grants from Brazilian research agencies CNPq and FAPEMIG. MK was supported by a NIDDK T32 grant through June 2014. RGN acknowledges that this work was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. KK acknowledges the Government of India for giving him a University Grant Commission Junior Research Fellowship. GDT acknowledges support from NYU's US National Institute of Environmental Health Sciences Center grant ( number ES00260 ). HC and SJL are supported by the intramural programme of NIH, the National Institute of Environmental Health Sciences. KD is supported by a Wellcome Trust Fellowship in Public Health and Tropical Medicine ( grant number 099876 ). HW, AF, HE, and FC are affiliated with the Queensland Centre for Mental Health Research, which receives funding from the Queensland Department of Health. LAR acknowledges the support of Qatar National Research Fund ( 04-924-3-251 ). TF is grateful to the Swiss National Science Foundation for an Early and an Advanced Postdoc Mobility fellowship (project number PBBSP3-146869 and P300P3-154634). IA acknowledges the UK National Institute for Health Research and the Medical Research Council for funding. HWH acknowledges support from Parnassia Psychiatric Institute, The Hague, Netherlands; the Department of Psychiatry, University of Groningen, University Medical Center Groningen, Netherlands; and the Department of Epidemiology, Columbia University, New York, NY, USA. JM has received support from the National Health and Medical Research Council John Cade Fellowship APP1056929 . UM acknowledges funding from the German National Cohort Consortium. BOA acknowledges a Susan G. Komen for the Cure Research Program – Leadership Grant (number SAC110001). AJC's work on GBD was funded by Health Effects Institute and the William and Flora Hewlett Foundation. RD acknowledges that funding from the US Deptartment of Veterans Affairs supports his salary. RD acknowledges funding from the American Parkinson's Disease Association for support of this work. MK receives research support from the Academy of Finland, the Swedish Research Council, Alzheimer Association, and AXA Research Fund. SS receives postdoctoral funding from the Fonds de la recherche en santé du Québec. GA-C acknowledges funding and support from Health Sciences and Neurosciences (CISNEURO) Research Group, Cartagena de Indias, Colombia. No authors received additional compensation for their efforts. Publisher Copyright: © 2015 Elsevier Ltd.
PY - 2015/1/10
Y1 - 2015/1/10
N2 - Background Up-to-date evidence on levels and trends for age-sex-specific all-cause and cause-specific mortality is essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess whether there is epidemiological convergence across countries. Methods We estimated age-sex-specific all-cause mortality using the GBD 2010 methods with some refinements to improve accuracy applied to an updated database of vital registration, survey, and census data. We generally estimated cause of death as in the GBD 2010. Key improvements included the addition of more recent vital registration data for 72 countries, an updated verbal autopsy literature review, two new and detailed data systems for China, and more detail for Mexico, UK, Turkey, and Russia. We improved statistical models for garbage code redistribution. We used six different modelling strategies across the 240 causes; cause of death ensemble modelling (CODEm) was the dominant strategy for causes with sufficient information. Trends for Alzheimer's disease and other dementias were informed by meta-regression of prevalence studies. For pathogen-specific causes of diarrhoea and lower respiratory infections we used a counterfactual approach. We computed two measures of convergence (inequality) across countries: the average relative difference across all pairs of countries (Gini coefficient) and the average absolute difference across countries. To summarise broad findings, we used multiple decrement life-tables to decompose probabilities of death from birth to exact age 15 years, from exact age 15 years to exact age 50 years, and from exact age 50 years to exact age 75 years, and life expectancy at birth into major causes. For all quantities reported, we computed 95% uncertainty intervals (UIs). We constrained cause-specific fractions within each age-sex-country-year group to sum to all-cause mortality based on draws from the uncertainty distributions. Findings Global life expectancy for both sexes increased from 65·3 years (UI 65·0-65·6) in 1990, to 71·5 years (UI 71·0-71·9) in 2013, while the number of deaths increased from 47·5 million (UI 46·8-48·2) to 54·9 million (UI 53·6-56·3) over the same interval. Global progress masked variation by age and sex: for children, average absolute differences between countries decreased but relative differences increased. For women aged 25-39 years and older than 75 years and for men aged 20-49 years and 65 years and older, both absolute and relative differences increased. Decomposition of global and regional life expectancy showed the prominent role of reductions in age-standardised death rates for cardiovascular diseases and cancers in high-income regions, and reductions in child deaths from diarrhoea, lower respiratory infections, and neonatal causes in low-income regions. HIV/AIDS reduced life expectancy in southern sub-Saharan Africa. For most communicable causes of death both numbers of deaths and age-standardised death rates fell whereas for most non-communicable causes, demographic shifts have increased numbers of deaths but decreased age-standardised death rates. Global deaths from injury increased by 10·7%, from 4·3 million deaths in 1990 to 4·8 million in 2013; but age-standardised rates declined over the same period by 21%. For some causes of more than 100 000 deaths per year in 2013, age-standardised death rates increased between 1990 and 2013, including HIV/AIDS, pancreatic cancer, atrial fibrillation and flutter, drug use disorders, diabetes, chronic kidney disease, and sickle-cell anaemias. Diarrhoeal diseases, lower respiratory infections, neonatal causes, and malaria are still in the top five causes of death in children younger than 5 years. The most important pathogens are rotavirus for diarrhoea and pneumococcus for lower respiratory infections. Country-specific probabilities of death over three phases of life were substantially varied between and within regions. Interpretation For most countries, the general pattern of reductions in age-sex specific mortality has been associated with a progressive shift towards a larger share of the remaining deaths caused by non-communicable disease and injuries. Assessing epidemiological convergence across countries depends on whether an absolute or relative measure of inequality is used. Nevertheless, age-standardised death rates for seven substantial causes are increasing, suggesting the potential for reversals in some countries. Important gaps exist in the empirical data for cause of death estimates for some countries; for example, no national data for India are available for the past decade. Funding Bill & Melinda Gates Foundation.
AB - Background Up-to-date evidence on levels and trends for age-sex-specific all-cause and cause-specific mortality is essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess whether there is epidemiological convergence across countries. Methods We estimated age-sex-specific all-cause mortality using the GBD 2010 methods with some refinements to improve accuracy applied to an updated database of vital registration, survey, and census data. We generally estimated cause of death as in the GBD 2010. Key improvements included the addition of more recent vital registration data for 72 countries, an updated verbal autopsy literature review, two new and detailed data systems for China, and more detail for Mexico, UK, Turkey, and Russia. We improved statistical models for garbage code redistribution. We used six different modelling strategies across the 240 causes; cause of death ensemble modelling (CODEm) was the dominant strategy for causes with sufficient information. Trends for Alzheimer's disease and other dementias were informed by meta-regression of prevalence studies. For pathogen-specific causes of diarrhoea and lower respiratory infections we used a counterfactual approach. We computed two measures of convergence (inequality) across countries: the average relative difference across all pairs of countries (Gini coefficient) and the average absolute difference across countries. To summarise broad findings, we used multiple decrement life-tables to decompose probabilities of death from birth to exact age 15 years, from exact age 15 years to exact age 50 years, and from exact age 50 years to exact age 75 years, and life expectancy at birth into major causes. For all quantities reported, we computed 95% uncertainty intervals (UIs). We constrained cause-specific fractions within each age-sex-country-year group to sum to all-cause mortality based on draws from the uncertainty distributions. Findings Global life expectancy for both sexes increased from 65·3 years (UI 65·0-65·6) in 1990, to 71·5 years (UI 71·0-71·9) in 2013, while the number of deaths increased from 47·5 million (UI 46·8-48·2) to 54·9 million (UI 53·6-56·3) over the same interval. Global progress masked variation by age and sex: for children, average absolute differences between countries decreased but relative differences increased. For women aged 25-39 years and older than 75 years and for men aged 20-49 years and 65 years and older, both absolute and relative differences increased. Decomposition of global and regional life expectancy showed the prominent role of reductions in age-standardised death rates for cardiovascular diseases and cancers in high-income regions, and reductions in child deaths from diarrhoea, lower respiratory infections, and neonatal causes in low-income regions. HIV/AIDS reduced life expectancy in southern sub-Saharan Africa. For most communicable causes of death both numbers of deaths and age-standardised death rates fell whereas for most non-communicable causes, demographic shifts have increased numbers of deaths but decreased age-standardised death rates. Global deaths from injury increased by 10·7%, from 4·3 million deaths in 1990 to 4·8 million in 2013; but age-standardised rates declined over the same period by 21%. For some causes of more than 100 000 deaths per year in 2013, age-standardised death rates increased between 1990 and 2013, including HIV/AIDS, pancreatic cancer, atrial fibrillation and flutter, drug use disorders, diabetes, chronic kidney disease, and sickle-cell anaemias. Diarrhoeal diseases, lower respiratory infections, neonatal causes, and malaria are still in the top five causes of death in children younger than 5 years. The most important pathogens are rotavirus for diarrhoea and pneumococcus for lower respiratory infections. Country-specific probabilities of death over three phases of life were substantially varied between and within regions. Interpretation For most countries, the general pattern of reductions in age-sex specific mortality has been associated with a progressive shift towards a larger share of the remaining deaths caused by non-communicable disease and injuries. Assessing epidemiological convergence across countries depends on whether an absolute or relative measure of inequality is used. Nevertheless, age-standardised death rates for seven substantial causes are increasing, suggesting the potential for reversals in some countries. Important gaps exist in the empirical data for cause of death estimates for some countries; for example, no national data for India are available for the past decade. Funding Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=84920703518&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(14)61682-2
DO - 10.1016/S0140-6736(14)61682-2
M3 - Article
SN - 0140-6736
VL - 385
SP - 117
EP - 171
JO - Lancet
JF - Lancet
IS - 9963
ER -